Skip to content

Abstract 10390: Phenotypic Expression and Clinical Outcomes of AKAP9 Variants in Patients from a Tertiary Center in Mexico: A Case Series

Nov 2026 · Circulation · 0 citations

Abstract

Introduction: The A-kinase anchoring protein 9 (AKAP9) gene is located on chromosome 7q21.2. It contains 51 exons spanning 169.8 kb of the human genome and primarily encodes the Yotiao protein, also known as A-kinase anchoring protein 9. AKAP9 plays essential roles in the regulation of cardiac and vascular physiology, and recent evidence has associated AKAP9 variants with several pathophysiological cardiovascular conditions, including long QT syndrome (LQTS) and cardiomyopathic phenotypes. Patient Information: Eight patients (6 males and 2 females; age range, 6-49 years) harboring AKAP9 variants were evaluated at a tertiary cardiovascular referral center in Mexico. Clinical Findings: Clinical presentations included syncope (n=2), family history of sudden cardiac death (SCD) (n=4), chest pain and/or palpitations (n=3), progressive dyspnea (n=1), and aborted SCD (n=1). Diagnostic Assessment & Reasoning: All patients underwent comprehensive cardiovascular evaluation, including electrocardiography, Holter monitoring, transthoracic echocardiography, cardiac imaging, and genetic testing. Diagnoses included LQTS (n=5), dilated cardiomyopathy (DCM) (n=2), arrhythmogenic right ventricular cardiomyopathy (ARVC) (n=2), and an unclassified arrhythmic phenotype (n=1). Six AKAP9 variants were identified and classified as variants of uncertain significance (VUS) by Labcorp (formerly Invitae). Therapeutic Intervention(s): Management strategies included implantable cardioverter-defibrillator (ICD) implantation for secondary prevention in four patients, beta-blocker therapy in patients with LQTS, antiarrhythmic treatment with propafenone in one patient, guideline-directed medical therapy for heart failure in two patients, and clinical surveillance in asymptomatic carriers. Follow-up, Outcomes & Adverse Events: During follow-up, one patient with LQTS and DCM progressed to end-stage heart failure and underwent heart transplantation seven years after the initial presentation. Six patients remained clinically stable without documented arrhythmic events. One patient experienced a sustained ventricular tachycardia episode that was successfully terminated by appropriate ICD therapy. Discussion & Synthesis: The AKAP9 variants identified in this series were classified as VUS by Labcorp. However, recent evidence has linked AKAP9 to inherited cardiovascular disorders, particularly LQTS and ARVC. Notably, these associations are consistent with the phenotypes observed in our patients, in whom LQTS and ARVC were the predominant clinical manifestations. Additional functional studies are needed to clarify the pathogenicity of these variants and to better define the role of AKAP9 in the development and progression of inherited arrhythmic and cardiomyopathic disorders.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.